Compare Fluor Corporation Common Stock (FLR) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fluor Corporation Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Fluor Corporation Common Stock trades at $47.6 (market cap $6.65B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Fluor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluor Corporation Common Stock for 6 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FLR | HNGE | |
|---|---|---|
Market Cap | $6.65B | $8.48B |
Volume | 1,556,536 | 879,799 |
Sector | Industrials | Health |
52-Week High | $57.50 | $105.14 |
52-Week Low | $39.63 | $31.17 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.68B | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fluor Corporation (FLR) trades at $49.75, showing minimal daily movement with a 0.08% gain. The stock faces bearish technical signals but maintains analyst support with a $62.33 consensus price target. Recent Q2 2026 earnings beat expectations, though profitability remains challenged with negative margins. The company secured a significant $7.5 billion LNG Canada Phase 2 project, providing substantial future revenue visibility amid ongoing operational restructuring.
FLR presents a turnaround opportunity with strong backlog coverage but carries execution risks. The stock trades at attractive valuation multiples (P/S 0.49) with 53.6% analyst buy ratings, yet negative cash flow and margin pressures require careful monitoring. Near-term performance hinges on successful project execution and margin improvement from the shift to reimbursable contracts.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fluor Corporation Common Stock
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
